share_log

Irwin Naturals, Numinus, Field Trip: Sector Analyst Compares Footprints, Cash, Organic Growth

Benzinga Real-time News ·  Jan 24, 2023 12:07

The Analyst

AnalystPablo Zuanicfrom Cantor Fitzgerald kept an Overweight rating for Irwin Naturals (CSE:IWIN) (OTC:IWINF) but lowered its 12-month price target to US$6.00 (C$8.05) from US$6.20 "on adjusted estimates."

The Thesis

Zuanic highlighted the "potential approval of various forms of psychedelics-assisted therapy, which should provide a boost for the mental health clinics sector (where stocks remain mostly under the radar)."

Irwin Naturals remains focused on its "roll-up strategy" of the mental health clinics industry, but "it has pushed out targets (100 clinics by end of CY24 vs. CY23 before)," Zuanic said in his analyst note on Monday.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment